Tuesday, July 27, 2010 (Last Updated: 07/28/2010)
TUESDAY, July 27 (HealthDay News) -- Physicians tend to note pelvic-related adverse events in reasonable accordance with patients receiving hormone manipulation or external beam radiation therapy (EBRT) for prostate cancer, according to research published in the August issue of The Journal of Urology.
E. Andreas Svaboe Steinsvik, of the Oslo University Hospital in Norway, and colleagues analyzed data from men with locally advanced prostate cancer who were randomized to antiandrogen monotherapy or the same hormone treatment with EBRT. They included 333 men with ratings at baseline and 12- and 24-month follow-up and a sample of 305 men at the end of radiotherapy. Adverse events included urinary incontinence, erectile dysfunction, and bowel problems.
The researchers found that, at baseline, patient and physician ratings were in perfect agreement in 70 to 100 percent of cases. Perfect agreement was seen in 73 to 98 percent of cases at 12 months and 65 to 97 percent at 24 months. Physicians more commonly underrated than overrated adverse events compared to patient ratings, except for bowel problems, which they overrated at all points.
"In a randomized controlled trial involving EBRT and hormone manipulation, physicians recorded pelvis related adverse events in acceptable accordance with that of their patients with prostate cancer. The oncologist tendency to overestimate post-EBRT bowel problems needs further investigation. Our positive findings from a formal trial should not be transferred to daily clinical practice without further studies of discrepancies in routine clinical practice," the authors conclude.
A co-author disclosed financial relationships with several pharmaceutical companies.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.